Investment analysts at Jefferies Financial Group began coverage on shares of Tempest Therapeutics (NASDAQ:TPST – Get Free Report) in a research note issued on Thursday, Briefing.com reports. The firm set a “buy” rating and a $15.00 price target on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 258.00% from the stock’s previous close.
Separately, HC Wainwright raised their target price on shares of Tempest Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th.
Tempest Therapeutics Stock Performance
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last released its earnings results on Wednesday, November 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.07. On average, analysts expect that Tempest Therapeutics will post -1.93 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tempest Therapeutics
Several large investors have recently modified their holdings of the business. Susquehanna International Group LLP bought a new stake in shares of Tempest Therapeutics in the 1st quarter valued at about $26,000. Millennium Management LLC bought a new stake in shares of Tempest Therapeutics in the 2nd quarter valued at about $29,000. Geode Capital Management LLC grew its position in shares of Tempest Therapeutics by 52.9% in the 2nd quarter. Geode Capital Management LLC now owns 102,244 shares of the company’s stock worth $130,000 after buying an additional 35,372 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Tempest Therapeutics by 290.2% in the 2nd quarter. Renaissance Technologies LLC now owns 103,401 shares of the company’s stock worth $131,000 after buying an additional 76,901 shares during the last quarter. Finally, Worth Venture Partners LLC purchased a new position in shares of Tempest Therapeutics in the 2nd quarter worth approximately $129,000. Institutional investors own 28.73% of the company’s stock.
About Tempest Therapeutics
Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
- Five stocks we like better than Tempest Therapeutics
- How to Invest in Solar Energy
- Are these frigid Dow stocks in for a longer winter?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Can financial, healthcare, energy stocks rise as rates stay high?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why H&R Block Stock Looks More Attractive After Earnings Dip
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.